Statement: Laser Therapy is only used in cohort 1 of the primary trial,  neither cohort of the secondary trial make use of this.
Primary_evidence: INTERVENTION 1:    Laser Therapy Alone   therapist administered laser treatment   laser: therapist administered laser INTERVENTION 2:    Mld Alone   therapist administered manual lymphatic drainage   manual lymphatic drainage: therapist administered massage therapy
Secondary_evidence: INTERVENTION 1:    Part A Abemaciclib: HR+, HER2+ Breast Cancer   Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met. INTERVENTION 2:    Part B Abemaciclib: HR+, HER2- Breast Cancer   Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET).   Participants may continue to receive treatment until discontinuation criteria are met.